The estimated Net Worth of Charles Cashion is at least $20.3 mil dollars as of 9 January 2017. Charles Cashion owns over 42,424 units of Novabay Pharmaceuticals Inc stock worth over $20,334 and over the last 17 years Charles sold NBY stock worth over $0.
Charles has made over 2 trades of the Novabay Pharmaceuticals Inc stock since 2009, according to the Form 4 filled with the SEC. Most recently Charles exercised 42,424 units of NBY stock worth $42,000 on 9 January 2017.
The largest trade Charles's ever made was exercising 42,424 units of Novabay Pharmaceuticals Inc stock on 9 January 2017 worth over $42,000. On average, Charles trades about 1,113 units every 69 days since 2007. As of 9 January 2017 Charles still owns at least 42,424 units of Novabay Pharmaceuticals Inc stock.
You can see the complete history of Charles Cashion stock trades at the bottom of the page.
Charles's mailing address filed with the SEC is C/O NOVABAY PHARMACEUTICALS, INC., 5980 HORTON STREET, SUITE 550, EMERYVILLE, CA, 94608.
Over the last 18 years, insiders at Novabay Pharmaceuticals Inc have traded over $3,799,939 worth of Novabay Pharmaceuticals Inc stock and bought 24,568,662 units worth $26,237,091 . The most active insiders traders include Pharma (Singapore) Pte. Ltd..., Pioneer Pharma Holdings Ltd... y Pharma (Hong Kong) Co Ltd P.... On average, Novabay Pharmaceuticals Inc executives and independent directors trade stock every 57 days with the average trade being worth of $127,779. The most recent stock trade was executed by Paul E. Freiman on 11 May 2023, trading 858 units of NBY stock currently worth $411.
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
Novabay Pharmaceuticals Inc executives and other stock owners filed with the SEC include: